In vitro delivery of mTOR inhibitors by kidney-targeted micelles for autosomal dominant polycystic kidney disease
Open Access
- 20 February 2023
- journal article
- research article
- Published by Elsevier in SLAS Technology
- Vol. 28 (4) , 223-229
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complexNeuro-Oncology, 2015
- Everolimus and sirolimus in transplantation-related but differentExpert Opinion on Drug Safety, 2015
- In vivo biodistribution and clearance of peptide amphiphile micellesNanomedicine: Nanotechnology, Biology and Medicine, 2015
- Rapamycin: One Drug, Many EffectsCell Metabolism, 2014
- Equivalent Benefit of Rapamycin and a Potent mTOR ATP-Competitive Inhibitor, MLN0128 (INK128), in a Mouse Model of Tuberous SclerosisMolecular Cancer Research, 2013
- Everolimus in Patients with Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2010
- New approach for local delivery of rapamycin by bioadhesive PLGA-carbopol nanoparticlesDrug Delivery, 2009
- Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2008
- Strategies to Inhibit Cyst Formation in ADPKDClinical Journal of the American Society of Nephrology, 2008
- Clinical Pharmacokinetics of EverolimusClinical Pharmacokinetics, 2004